---
document_datetime: 2023-09-21 17:19:36
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/dynepo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: dynepo-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.1350963
conversion_datetime: 2025-12-19 11:36:37.828533
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| No      | Scope                                                                       | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|-----------------------------------------------------------------------------|---------------------|------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0020 | Update of Summary of Product Characteristics, Labelling and Package Leaflet | 24/01/2008          | 29/02/2008                               | no SPC, Labelling, PL            | longer This variation primarily concerns an update of the SPC following the completion of a class safety review by the PhVWP and the CHMP. The safety review was initiated because recent data show a consistent unexplained excess mortality in cancer patients with anaemia treated with epoetins, and that treatment of anaemia with epoetins in patients with chronic kidney disease to achieve relatively high target haemoglobin concentrations may be associated with an increase in the risk of mortality and cardiovascular morbidity. As a result, the main changes being implemented are: i) in section 4.1, to highlight that epoetins should be used only if associated with symptoms, ii) in Section 4.2 to establish a uniform target haemoglobin range for all epoetins, iii) in Section 4.4 to mention the observed negative benefit risk balance in patients treated with high target haemoglobin concentrations, and to remove safety statements that are relevant only for the treatment of anaemia associated with cancer, and iv) in section 5.1 to include the relevant results of the trials triggering the safety review. The package leaflet has been updated accordingly Additionally, sections 4.8 and 6.6 have also been amended to correct minor inconsistencies, as have the package leaflet and labelling. |
| II/0019 | product Change(s) to the manufacturing process for the finished product     | 21/02/2008          | 03/03/2008                               |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0014 | Change to the test procedure and/or specification of a starting material    | 21/06/2007          | 24/07/2007                               |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0010 | New presentation(s)                                                         | 22/02/2007          | 02/04/2007                               | SPC, Labelling, PL               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| R/0009  | Renewal of the Marketing Authorisation                                      | 22/02/2007          | 17/04/2007                               | SPC, Annex II,                   | Based upon the data that have become available since the granting of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

Medicinal product no longer authorised Dynepo Procedural steps taken and scientific information after the authorisation MAJOR CHANGES 1 1 Major changes e.g. Type II variations, Annex II applications, Renewals and Annual Reassessments 2 SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet)

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                          | Opinion issued on   | Commission Decision Issued/ amended on   | Product Information affected 2   | Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------|--------------------------------------------------------------------------------|---------------------|------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|         |                                                                                |                     | no                                       | Labelling, PL                    | longer authorised the initial Marketing Authorisation, the CHMP considers that the benefit/risk balance of Dynepo remains positive, but considers that its safety profile is to be closely monitored for the following reasons: Dynepo was authorised in the EU on 18 March 2002. However, the medicinal product was not yet launched on the European market as well as on any other market worldwide. Therefore, post-marketing experience in the EU and worldwide is not available at the time of this renewal. The only available safety data was collected from clinical trials. These data are limited and cannot be used to assess post marketing safety of Dynepo. Moreover, data on long-term exposure to Dynepo is limited. Although there have been no significant safety concerns highlighted, the CHMP considers the available safety data not sufficient to support a renewal with unlimited validity. The CHMP decided that Dynepo should not be renewed with unlimited validity at this point. The MAHwill therefore be required to submit one additional five-year renewal, in line with the requirements of current legislation. |
| II/0007 | Change(s) to the manufacturing process for the finished product                | product 21/09/2006  | 23/10/2006                               | Annex II, PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0006 | Change(s) to the test method(s) and/or specifications for the finished product | 21/09/2006          | 23/10/2006                               | SPC, PL                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0005 | Change(s) to the test method(s) and/or specifications for the active substance | 21/09/2006          | 25/09/2006                               |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0004 | Change(s) to the manufacturing process for the active substance                | 21/09/2006          | 23/10/2006                               | Annex II                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0003 | Update of Summary of Product Characteristics, Labelling and Package Leaflet    | 27/04/2006          | 08/06/2006                               | SPC, Annex II, Labelling, PL     | Update of Summary of Product Characteristics, Labelling and Package Leaflet following PhVWP assessment of the risk of tumour growth progression and thromoembolic events in cancer patients. Sections requested to update were 4.2, 4.4 and 5.1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| T/0001  | Transfer of Marketing Authorisation Holder                                     | 10/08/2005          | 13/09/2005                               | SPC, Labelling, PL               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| No      | Scope                                                                                                                                                                                  | authorised Product Information affected 2   | Date 4     |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|------------|
| IB/0022 | 12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening 37_a_Change in the specification of the finished product - tightening of specification limits |                                             | 28/01/2008 |
| IB/0021 | 12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening                                                                                               |                                             | 28/01/2008 |
| IA/0017 | 08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                                                                          | Annex II, PL                                | 05/06/2007 |
| N/0013  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                       | PL                                          | 16/03/2007 |
| IA/0012 | 07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                  |                                             | 18/01/2007 |
| IA/0011 | 05_Change in the name and/or address of a manufacturer of the finished product                                                                                                         | Annex II, PL                                | 07/12/2006 |
| N/0008  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                       | Labelling, PL                               | 04/09/2006 |
| IA/0002 | 47_a_Deletion of a pharmaceutical form                                                                                                                                                 | SPC, Labelling, PL                          | 27/10/2005 |

## Medicinal product no longer authorised MINOR CHANGES 3 No Scope IB/0022 12\\_a\\_Change in spec. of active subst./agent used in manuf. of active subst. - tightening 37\\_a\\_Change in the specification of the finished product - tightening of specification limits IB/0021 12\\_a\\_Change in spec. of active subst./agent used in manuf. of active subst. - tightening IA/0017 08\\_b\\_01\\_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing N/0013 Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) IA/0012 07\\_a\\_Replacement/add. of manufacturing site: Secondary packaging site IA/0011 05\\_Change in the name and/or address of a manufacturer of the finished product N/0008 Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) IA/0002 47\\_a\\_Deletion of a pharmaceutical form 3 Minor changes e.g. Type I variations and Notifications 4 Date of entry into force of the change